UBE2L6 and Insulin resistance: Among the six prognostic signatures, Ubiquitin/ISG15-conjugating enzyme E2 L6 (Ube2L6) has been reported to promote insulin resistance and hepatic steatosis and is related to cisplatin resistance (Murakami et al., 2020; Wei et al., 2021).